Join the Class Action Against Capricor Therapeutics Today!

Capricor Therapeutics Faces Securities Class Action Lawsuit

Attention investors! A securities class action lawsuit has been initiated on behalf of investors who acquired shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024, and July 10, 2025. This legal action was launched to address serious allegations regarding the company's misrepresentation of critical data.

Understanding the Allegations

The lawsuit alleges that the index had misleading information pertaining to the safety and efficacy data from their Phase 2 HOPE-2 trial study of deramiocel, a leading cell therapy designed to treat cardiomyopathy, particularly for those affected by Duchenne muscular dystrophy.

Why is This Important?

For investors, details regarding the efficacy of treatments under development are paramount. Misleading information could greatly impact financial investments and personal stakes in the company’s future. Thus, those who purchased shares during this time frame may have experienced losses and should seriously evaluate their options.

Are You Affected by This Situation?

It’s essential to ask yourself a few important questions. Did you own shares of Capricor Therapeutics during the specified period? Have you suffered financial losses as a result? If the answer is yes, you may be eligible to join the class action.

Potential Benefits of Joining the Class Action

Participating in a class action lawsuit could provide a pathway to recovery for your losses. It's important to note that engaging in this litigation process does not require individuals to serve as lead plaintiffs. Your participation means taking a stand, and you might share in any potential recovery without active involvement in the proceedings.

Time-Sensitive Information

Keep in mind that individuals interested in serving as lead plaintiffs must take action by a specific date—September 15, 2025. If you're considering this option, it’s crucial to file necessary documents promptly. Otherwise, you remain a passive member of the class.

No Financial Burden to Join

Another reassuring factor for shareholders is that all representation operates on a contingency fee basis. This means you incur no fees or expenses unless there's a recovery. That makes participating risk-free concerning financial obligation.

About Bernstein Liebhard LLP

For over three decades, Bernstein Liebhard LLP has made a significant mark in the legal arena, recovering over $3.5 billion for its clients. Their expertise includes working not only with individual investors but also representing large public pension funds. The firm has accrued numerous accolades for its achievements, securing a spot on The National Law Journal's "Plaintiffs' Hot List" multiple times.

Contacting Bernstein Liebhard

If you wish to learn more about your options or have any questions regarding this lawsuit, please reach out to Peter Allocco, the Investor Relations Manager. You can connect with him at (212) 951-2030 or email at pallocco@bernlieb.com.

Frequently Asked Questions

What is the class action lawsuit about?

The lawsuit addresses allegations of misleading safety and efficacy data related to Capricor Therapeutics’ primary drug candidate.

How can I join the class action?

You can join by confirming your investment during the specified time frame and contacting the legal team for more information.

Is there a cost to participate in the lawsuit?

No, participation is on a contingency basis, which means there are no upfront costs.

What if I do not want to be a lead plaintiff?

You can still join the class action without being a lead plaintiff and share in any potential recovery.

Who can I contact for more information?

You can reach out to Peter Allocco at Bernstein Liebhard LLP for any inquiries related to the class action.

About The Author

Hello Kelly Martin here, a financial and publicly traded company specialist committed to writing with clarity and sage advice. Having a wealth of experience and a thorough grasp of corporate dynamics and the financial environment, my main goal in writing blog posts and articles is to provide insightful analysis together with useful guidance. My objective is to arm readers with the information they need to comprehend the complexities of publicly traded companies and make wise financial decisions.

Writing for several financial blogs has let me interact with a wide range of readers, from novice investors to seasoned pros looking for fresh perspectives. My goal is to make corporate analysis and finance understandable and interesting so you may confidently negotiate the intricacies of the financial world. I appreciate you traveling with me toward success and financial literacy.

Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.